NetworkNewsBreaks Archive - Page 202 of 2120

WednesdayMar 26, 2025 10:45 am

NetworkNewsBreaks – Amazon.com Inc. (NASDAQ: AMZN) Stock Rebounds Amid Positive AI Outlook Post-Nvidia Conference

Amazon.com (NASDAQ: AMZN) experienced a stock uptick following analyst optimism regarding its artificial intelligence (AI) prospects after Nvidia's recent GTC conference. Monness Crespi Hardt analyst Brian White highlighted Amazon Web Services' (AWS) potential to benefit from the growing generative AI sector, reiterating a buy rating with a price target of $215. Despite a seven-week decline in Amazon's stock amid a broader market downturn, analysts remain positive about the company's long-term growth, particularly in AI. As of 10:09 AM EDT on March 26, 2025, Amazon's stock is trading at $202.94, reflecting a decrease of $2.77 (1.35%) from the previous close. To…

WednesdayMar 26, 2025 10:35 am

NetworkNewsBreaks – Tesla Inc. (NASDAQ: TSLA) Stock Rises for Fifth Consecutive Session Amid Analyst Optimism

Tesla (NASDAQ: TSLA) has achieved its fifth consecutive day of stock gains, closing at $288.14 on Tuesday, March 25, 2025. This 3.5% increase brings the stock up 28% over the past five days, reversing a two-month decline. The rally comes despite reports of falling sales in the European Union for the second consecutive month. Analysts attribute the surge to CEO Elon Musk's encouragement for employees to retain their shares and confidence in Tesla's self-driving and robotics technology. Key resistance levels to monitor include $300, $385, and $680, while support levels are identified at $217 and $155. As of 10:13…

WednesdayMar 26, 2025 10:32 am

NetworkNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Encouraging Progress in Brain Cancer Trial with City of Hope

Calidi Biotherapeutics (NYSE American: CLDI) announced promising early results from a phase 1 clinical trial evaluating its CLD-101 investigational agent, a neural stem cell-based oncolytic virotherapy, in collaboration with City of Hope. The trial, targeting recurrent high-grade glioma, is the first to assess multiple weekly intracerebral doses of CLD-101. Fourteen participants have been treated so far with no safety concerns, and the study is now enrolling patients into the highest dosing cohort. The trial has expanded to Northwestern University and Stanford University, and is supported by a $12 million grant from the California Institute for Regenerative Medicine. Calidi retains licensing…

WednesdayMar 26, 2025 10:21 am

NetworkNewsBreaks – Thumzup Media Corp. (NASDAQ: TZUP) Unveils Lifestyle AI Agent Marketplace and Files Trademarks for GibberAds

Thumzup (NASDAQ: TZUP) announced the development of its patent-pending Lifestyle AI Agent Marketplace, a next-gen platform designed to deliver hyper-personalized experiences using specialized AI agents. The system will feature premium AI "swarms" that collaborate to create lifestyle plans in areas like travel, wellness, and entertainment, while offering real-time promotions to users from participating businesses. Thumzup also filed trademark applications for its AI-powered marketing tools, Gibberlink Advertising™ and GibberAds™, both of which will enable dynamic engagement between users, influencers, and advertisers. Monetization strategies include influencer affiliate programs, business AI accounts, and transaction-based commissions. To view the full press release, visit https://nnw.fm/4yoWv …

WednesdayMar 26, 2025 10:05 am

NetworkNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Reports Record Revenue Surge Driven by Commercial EV Sales

Mullen Automotive (NASDAQ: MULN) announced record GAAP revenue of $3.18 million as of March 21, 2025, marking a 189% increase over its total 2024 revenue of $1.1 million. The surge reflects strong momentum in sales of its commercial EVs, including the Mullen ONE cargo van and Mullen THREE cab chassis truck, both of which are fully certified under U.S. emissions and safety standards. The company also highlighted progress from its Bollinger division, which began delivering its all-electric Class 4 B4 Chassis Cab truck in October. CEO David Michery stated the fiscal Q2 will close as the company’s strongest revenue quarter…

TuesdayMar 25, 2025 2:05 pm

NetworkNewsBreaks – Adageis Is Bringing AI to the Forefront of Value-Based Care

Adageis, a leading healthcare technology company, is at the forefront of an industry shift as providers increasingly prioritize specific, high-impact artificial intelligence (“AI”) applications that enhance patient care and financial performance. The company was featured in a recent article that discussed its innovative AI-driven solutions through its ProActive Care Platform, which offers practical applications that directly impact revenue generation and patient care. Adageis’ AI solutions stand distinct in providing key competencies in several areas including risk identification and early intervention, revenue tracking and forecasting, clinical decision support, administrative task automation, and continuous patient monitoring. Adageis’ platform demonstrates how AI can…

TuesdayMar 25, 2025 1:20 pm

NetworkNewsBreaks – MoneyShow Event to Spotlight Insights for Navigating 2025 Market Dynamics

MoneyShow, a premier producer of financial conferences for affluent investors, active traders, and financial advisors, has announced the return of Outlook 2025: Big Market Trends, Bold Investment Ideas. The two-day event, set to take place at the Hilton DFW Lakes in Dallas on Apr. 4-5, 2025, will provide actionable insights for navigating the opportunities and challenges of the new year. “Following the inauguration of President Trump, there has been increasing uncertainty and volatility in the markets. Investors are seeking answers about how important economic and political forces will influence their portfolios in 2025,” said MoneyShow’s Editor-in-Chief Mike Larson. “At this…

TuesdayMar 25, 2025 11:03 am

NetworkNewsBreaks – SolarBank Corp. (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) Closes $8.5 Million Direct Offering with Institutional Investor

Disseminated on behalf of SolarBank Corporation SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2) has closed a registered direct offering with a single institutional investor, securing approximately $8.5 million in gross proceeds. The investor, backed by a bulge bracket investment bank and active in the energy sector, purchased 2,394,367 common shares and an equal number of warrants at a combined price of $3.55 per share. The warrants are immediately exercisable at $4.45 per share and expire in five years, potentially generating up to an additional $10.65 million. SolarBank plans to use the proceeds to support battery energy storage system projects,…

TuesdayMar 25, 2025 10:43 am

NetworkNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Phase 2 Results for Berubicin in Glioblastoma Trial

CNS Pharmaceuticals (NASDAQ: CNSP) announced results from its Phase 2 clinical trial evaluating Berubicin for recurrent or progressive Glioblastoma Multiforme (GBM). While the study did not meet its primary endpoint of statistically significant improvement in overall survival compared to standard-of-care Lomustine, Berubicin showed comparable results across key clinical outcomes, including in patients with poor tumor markers. Importantly, no cardiotoxicity was observed, a major concern with other anthracyclines, and the safety profile remained favorable. The company plans to continue analysis and explore further development of Berubicin and its pipeline candidate TPI 287 for CNS malignancies. To view the full press release,…

TuesdayMar 25, 2025 9:57 am

NetworkNewsBreaks – Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) Hosts Investor Call Highlighting Actimab-A Clinical Progress and Expansion into Solid Tumors

Actinium Pharmaceuticals (NYSE AMERICAN: ATNM), a leader in targeted radiotherapies, will hold an investor call today at 8:00 a.m. ET featuring Dr. Ehab Atallah, Professor of Medicine at the Medical College of Wisconsin and principal investigator of the Actimab-A + CLAG-M trial for relapsed/refractory acute myeloid leukemia (r/r AML). Dr. Atallah will present updated clinical results, including long-term survival data and plans for a pivotal Phase 2/3 trial under Actinium's cooperative research and development agreement ("CRADA") with the National Cancer Institute. Actinium's management will also discuss the launch of its Actimab-A solid tumor program, which includes trials combining Actimab-A with…

Financial news and publishing for public and private companies

Contact us: 512.354.7000

NetworkNewsBreaks